Remedy Entertainment PLC (STU:8P8)

Q4 2024 Remedy Entertainment Oyj Earnings Call Transcript

Feb 12, 2025 / 10:00 AM GMT

Release Date Price: €12.62 (-0.47%)

Transcript

Key Points

Positve

Remedy Entertainment PLC (FRA:8P8) reported a 13% increase in revenue for Q4 2024, reaching €11.7 million.
Alan Wake 2 sales exceeded 2 million units, recouping its development and marketing costs, and began accruing royalty income.
The company acquired full rights to the Control franchise, enabling future self-publishing opportunities.
A strategic partnership with Annapurna Pictures was formed, financing 50% of Control 2's development and expanding the franchise into film and television.
Remedy Entertainment PLC (FRA:8P8) successfully transitioned to self-publishing, providing higher financial upside and control over commercialization.

Negative

Operating profit for Q4 2024 was negative €1.4 million, despite improvements from the previous year.
Royalties decreased by €1.2 million compared to the previous year, impacting overall revenue.
The gaming industry faced a challenging economic climate in early 2024, making it difficult to secure favorable financing for self-publishing.
The company is still ramping up its publishing operations, which may lead to increased operating expenses in 2025.
There is potential for high variation in working capital levels due to timing differences in development fees and royalties.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

REMEDY.HE - Remedy Entertainment Oyj
Q4 2024 Remedy Entertainment Oyj Earnings Call
Feb 12, 2025 / 10:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello everyone and thank you for joining this Remedy Entertainment Webcast. My name is Lisaaranda and I run the investor relations at Remedy. Today we will go through Remedy's financial statements for January, December 2024.

With me here are Terro Bertala, Remedy CEO, and Santo Car Lionpa Remedy CFO. There will be time for questions and answers after the presentations.

Get off the floor is yours.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Lisa. Welcome, everyone, also on my my behalf.

All right.

Let's first have a

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.